Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Pieris Pharmaceuticals GmbH

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. *

 

Period Start 2001-01-01 established_pre
  Group Pieris (Group)
  Predecessor Pieris AG
Products Industry Anticalin® scaffold technology
  Industry 2 Anticalin® therapeutic protein
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Schalper, Claus (XL-protein 201410 Managing Director (CEO) before Pieris 201101 CFO)
     
Region Region Freising
  Country Germany
  Street 30 Lise-Meitner-Str.
  City 85354 Freising
  Tel +49-8161-1411-400
    Address record changed: 2018-09-12
     
Basic data Employees n. a.
     
    * Document for �About Section�: Pieris Pharmaceuticals, Inc.. (8/10/17). "Press Release: Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer". Boston, MA.
     
   
Record changed: 2018-10-31

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top